{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:27:12Z","timestamp":1767853632719,"version":"3.49.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Military Infectious Diseases Research Program","award":["Project numbers F0299_12-NM"],"award-info":[{"award-number":["Project numbers F0299_12-NM"]}]},{"name":"Military Infectious Diseases Research Program","award":["F0389_14_NM"],"award-info":[{"award-number":["F0389_14_NM"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12936-017-1911-z","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T12:05:50Z","timestamp":1499083550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model"],"prefix":"10.1186","volume":"16","author":[{"given":"Keith","family":"Limbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Stefaniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelle B.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaojie","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Krepkiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Ekberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Torano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damodar","family":"Ettyreddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalpana","family":"Gowda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharvari","family":"Sonawane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnel","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Abot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Sedegah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Hollingdale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Moormann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Vulule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Villasante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Richie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas E.","family":"Brough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph T.","family":"Bruder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,3]]},"reference":[{"key":"1911_CR1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMra1204186","volume":"368","author":"GJ Nabel","year":"2013","unstructured":"Nabel GJ. Designing tomorrow\u2019s vaccines. N Engl J Med. 2013;368:551\u201360.","journal-title":"N Engl J Med"},{"key":"1911_CR2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1086\/589862","volume":"47","author":"SA Plotkin","year":"2008","unstructured":"Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47:401\u20139.","journal-title":"Clin Infect Dis"},{"key":"1911_CR3","doi-asserted-by":"crossref","first-page":"e5856","DOI":"10.1371\/journal.pone.0005856","volume":"4","author":"Z Xing","year":"2009","unstructured":"Xing Z, McFarland CT, Sallenave JM, Izzo A, Wang J, McMurray DN. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis. PLoS One. 2009;4:e5856.","journal-title":"PLoS One"},{"key":"1911_CR4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","volume":"473","author":"SG Hansen","year":"2011","unstructured":"Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011;473:523\u20137.","journal-title":"Nature"},{"key":"1911_CR5","doi-asserted-by":"crossref","first-page":"e55571","DOI":"10.1371\/journal.pone.0055571","volume":"8","author":"I Chuang","year":"2013","unstructured":"Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, et al. DNA prime\/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS ONE. 2013;8:e55571.","journal-title":"PLoS ONE"},{"key":"1911_CR6","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","volume":"4","author":"KJ Ewer","year":"2013","unstructured":"Ewer KJ, O\u2019Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, et al. Protective CD8+\u00a0T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun. 2013;4:2836.","journal-title":"Nat Commun"},{"key":"1911_CR7","doi-asserted-by":"crossref","first-page":"e106241","DOI":"10.1371\/journal.pone.0106241","volume":"9","author":"M Sedegah","year":"2014","unstructured":"Sedegah M, Hollingdale MR, Farooq F, Ganeshan H, Belmonte M, Kim Y, et al. Sterile immunity to malaria after DNA prime\/adenovirus boost immunization is associated with effector memory CD8+ T cells targeting AMA1 class I epitopes. PLoS ONE. 2014;9:e106241.","journal-title":"PLoS ONE"},{"key":"1911_CR8","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/infdis\/jiu293","volume":"210","author":"EM Bijker","year":"2014","unstructured":"Bijker EM, Teirlinck AC, Schats R, van Gemert GJ, van de Vegte-Bolmer M, van Lieshout L, et al. Cytotoxic markers associate with protection against malaria in human volunteers immunized with Plasmodium falciparum sporozoites. J Infect Dis. 2014;210:1605\u201315.","journal-title":"J Infect Dis"},{"key":"1911_CR9","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359\u201365.","journal-title":"Science"},{"key":"1911_CR10","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/JVI.77.11.6305-6313.2003","volume":"77","author":"DR Casimiro","year":"2003","unstructured":"Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol. 2003;77:6305\u201313.","journal-title":"J Virol"},{"key":"1911_CR11","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.4049\/jimmunol.143.12.4263","volume":"143","author":"WR Weiss","year":"1989","unstructured":"Weiss WR, Good MF, Hollingdale MR, Miller LH, Berzofsky JA. Genetic control of immunity to Plasmodium yoelii sporozoites. J Immunol. 1989;143:4263\u20136.","journal-title":"J Immunol."},{"key":"1911_CR12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0165-2478(90)90087-7","volume":"25","author":"SL Hoffman","year":"1990","unstructured":"Hoffman SL, Weiss W, Mellouk S, Sedegah M. Irradiated sporozoite vaccine induces cytotoxic T lymphocytes that recognize malaria antigens on the surface of infected hepatocytes. Immunol Lett. 1990;25:33\u20138.","journal-title":"Immunol Lett"},{"key":"1911_CR13","doi-asserted-by":"crossref","first-page":"e31247","DOI":"10.1371\/journal.pone.0031247","volume":"7","author":"WR Weiss","year":"2012","unstructured":"Weiss WR, Jiang CG. Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS One. 2012;7:e31247.","journal-title":"PLoS One"},{"key":"1911_CR14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1600-065X.2008.00671.x","volume":"225","author":"MG Overstreet","year":"2008","unstructured":"Overstreet MG, Cockburn IA, Chen YC, Zavala F. Protective CD8+ T cells against Plasmodium liver stages: immunobiology of an \u2018unnatural\u2019 immune response. Immunol Rev. 2008;225:272\u201383.","journal-title":"Immunol Rev"},{"key":"1911_CR15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fimmu.2012.00370","volume":"3","author":"U Krzych","year":"2012","unstructured":"Krzych U, Dalai S, Zarling S, Pichugin A. Memory CD8 T cells specific for plasmodia liver-stage antigens maintain protracted protection against malaria. Front Immunol. 2012;3:370.","journal-title":"Front Immunol."},{"key":"1911_CR16","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.4049\/jimmunol.158.3.1268","volume":"158","author":"EG Rodrigues","year":"1997","unstructured":"Rodrigues EG, Zavala F, Eichinger D, Wilson JM, Tsuji M. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J Immunol. 1997;158:1268\u201374.","journal-title":"J Immunol."},{"key":"1911_CR17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0014-4894(89)90118-5","volume":"68","author":"L Schofield","year":"1989","unstructured":"Schofield L. T cell immunity to malaria sporozoites. Exp Parasitol. 1989;68:357\u201364.","journal-title":"Exp Parasitol"},{"key":"1911_CR18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1073\/pnas.85.2.573","volume":"85","author":"WR Weiss","year":"1988","unstructured":"Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF. CD8+ T cells (cytotoxic\/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA. 1988;85:573\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1911_CR19","doi-asserted-by":"crossref","first-page":"9090","DOI":"10.1073\/pnas.1303858110","volume":"110","author":"IA Cockburn","year":"2013","unstructured":"Cockburn IA, Amino R, Kelemen RK, Kuo SC, Tse SW, Radtke A, et al. In vivo imaging of CD8+ T cell-mediated elimination of malaria liver stages. Proc Natl Acad Sci USA. 2013;110:9090\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1911_CR20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.exppara.2009.11.009","volume":"126","author":"M Tsuji","year":"2010","unstructured":"Tsuji M. A retrospective evaluation of the role of T cells in the development of malaria vaccine. Exp Parasitol. 2010;126:421\u20135.","journal-title":"Exp Parasitol"},{"key":"1911_CR21","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0264-410X(01)00450-9","volume":"20","author":"SC Gilbert","year":"2002","unstructured":"Gilbert SC, Schneider J, Hannan CM, Hu JT, Plebanski M, Sinden R, et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine. 2002;20:1039\u201345.","journal-title":"Vaccine."},{"key":"1911_CR22","doi-asserted-by":"crossref","first-page":"7648","DOI":"10.1073\/pnas.95.13.7648","volume":"95","author":"M Sedegah","year":"1998","unstructured":"Sedegah M, Trevor J, Kaur M, Hedstrom R, Hobart P, Tine J, et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA. 1998;95:7648\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1911_CR23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4161\/hv.6.1.10116","volume":"6","author":"AV Hill","year":"2010","unstructured":"Hill AV, Reyes-Sandoval A, O\u2019Hara G, Ewer K, Lawrie A, Goodman A, et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin. 2010;6:78\u201383.","journal-title":"Hum Vaccin."},{"key":"1911_CR24","doi-asserted-by":"crossref","first-page":"e33920","DOI":"10.1371\/journal.pone.0033920","volume":"7","author":"JT Bruder","year":"2012","unstructured":"Bruder JT, Semenova E, Chen P, Limbach K, Patterson NB, Stefaniak ME, et al. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses. PLoS ONE. 2012;7:e33920.","journal-title":"PLoS ONE"},{"key":"1911_CR25","doi-asserted-by":"crossref","first-page":"e6559","DOI":"10.1371\/journal.pone.0006559","volume":"4","author":"G Jiang","year":"2009","unstructured":"Jiang G, Shi M, Conteh S, Richie N, Banania G, Geneshan H, et al. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS ONE. 2009;4:e6559.","journal-title":"PLoS ONE"},{"key":"1911_CR26","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1371\/journal.pmed.0010033","volume":"1","author":"VS Moorthy","year":"2004","unstructured":"Moorthy VS, Imoukhuede EB, Milligan P, Bojang K, Keating S, Kaye P, et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA\/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 2004;1:e33.","journal-title":"PLoS Med."},{"key":"1911_CR27","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.vaccine.2006.03.029","volume":"24","author":"P Bejon","year":"2006","unstructured":"Bejon P, Mwacharo J, Kai OK, Todryk S, Keating S, Lang T, et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1\u20136\u00a0year old children in a malaria endemic area. Vaccine. 2006;24:4709\u201315.","journal-title":"Vaccine."},{"key":"1911_CR28","doi-asserted-by":"crossref","first-page":"7514","DOI":"10.1016\/j.vaccine.2011.03.083","volume":"29","author":"DW Porter","year":"2011","unstructured":"Porter DW, Thompson FM, Berthoud TK, Hutchings CL, Andrews L, Biswas S, et al. A human phase I\/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine. 2011;29:7514\u201322.","journal-title":"Vaccine."},{"key":"1911_CR29","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","volume":"7","author":"SH Sheehy","year":"2012","unstructured":"Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O\u2019Hara GA, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE. 2012;7:e31208.","journal-title":"PLoS ONE"},{"key":"1911_CR30","doi-asserted-by":"crossref","first-page":"e57726","DOI":"10.1371\/journal.pone.0057726","volume":"8","author":"C Ogwang","year":"2013","unstructured":"Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, et al. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS ONE. 2013;8:e57726.","journal-title":"PLoS ONE"},{"key":"1911_CR31","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1073\/pnas.0406381102","volume":"102","author":"DP Webster","year":"2005","unstructured":"Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA. 2005;102:4836\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1911_CR32","doi-asserted-by":"crossref","first-page":"e25868","DOI":"10.1371\/journal.pone.0025868","volume":"6","author":"C Tamminga","year":"2011","unstructured":"Tamminga C. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS One. 2011;6:e25868.","journal-title":"PLoS One"},{"key":"1911_CR33","unstructured":"WHO. Preferred product characteristics for malaria vaccines. 2014. Accessed at http:\/\/www.who.int\/immunization\/documents\/innovation\/WHO_IVB_14.09\/en\/ ."},{"key":"1911_CR34","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","volume":"77","author":"R Vogels","year":"2003","unstructured":"Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol. 2003;77:8263\u201371.","journal-title":"J Virol"},{"key":"1911_CR35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/CDLI.11.2.351-357.2004","volume":"11","author":"E Nwanegbo","year":"2004","unstructured":"Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States. Clin Diagn Lab Immunol. 2004;11:351\u20137.","journal-title":"Clin Diagn Lab Immunol"},{"key":"1911_CR36","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3201\/eid1210.060078","volume":"12","author":"Z Xiang","year":"2006","unstructured":"Xiang Z, Li Y, Cun A, Yang W, Ellenberg S, Switzer WM, et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis. 2006;12:1596\u20139.","journal-title":"Emerg Infect Dis"},{"key":"1911_CR37","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","volume":"29","author":"DH Barouch","year":"2011","unstructured":"Barouch DH, Kik SV, Weverling GJ, Dilan R, King SL, Maxfield LF, et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011;29:5203\u20139.","journal-title":"Vaccine."},{"key":"1911_CR38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/mt.2013.142","volume":"22","author":"TR Johnson","year":"2014","unstructured":"Johnson TR, Rangel D, Graham BS, Brough DE, Gall JG. Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol Ther. 2014;22:196\u2013205.","journal-title":"Mol Ther"},{"key":"1911_CR39","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.1202861","volume":"190","author":"KM Quinn","year":"2013","unstructured":"Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol. 2013;190:2720\u201335.","journal-title":"J Immunol."},{"key":"1911_CR40","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/509258","volume":"194","author":"AT Catanzaro","year":"2006","unstructured":"Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006;194:1638\u201349.","journal-title":"J Infect Dis"},{"key":"1911_CR41","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(08)61592-5","volume":"372","author":"MJ McElrath","year":"2008","unstructured":"McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a case\u2013cohort analysis. Lancet. 2008;372:1894\u2013905.","journal-title":"Lancet"},{"key":"1911_CR42","doi-asserted-by":"crossref","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","volume":"109","author":"DE Zak","year":"2012","unstructured":"Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, et al. Merck Ad5\/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity. Proc Natl Acad Sci USA. 2012;109:E3503\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1911_CR43","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","volume":"81","author":"P Abbink","year":"2007","unstructured":"Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81:4654\u201363.","journal-title":"J Virol"},{"key":"1911_CR44","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","volume":"85","author":"TW Geisbert","year":"2011","unstructured":"Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011;85:4222\u201333.","journal-title":"J Virol"},{"key":"1911_CR45","doi-asserted-by":"crossref","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","volume":"4","author":"S Colloca","year":"2012","unstructured":"Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012;4:115ra2.","journal-title":"Sci Transl Med"},{"key":"1911_CR46","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","volume":"20","author":"DA Stanley","year":"2014","unstructured":"Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20:1126\u20139.","journal-title":"Nat Med"},{"key":"1911_CR47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.virol.2013.05.041","volume":"444","author":"D McVey","year":"2013","unstructured":"McVey D, Cranfield MR, Torano H, Kuete HM, Lee GP, Glenn A, et al. Adenoviruses isolated from wild gorillas are closely related to human species C viruses. Virology. 2013;444:119\u201323.","journal-title":"Virology"},{"key":"1911_CR48","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1128\/IAI.70.7.3493-3499.2002","volume":"70","author":"M Sedegah","year":"2002","unstructured":"Sedegah M, Brice GT, Rogers WO, Doolan DL, Charoenvit Y, Jones TR, et al. Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8(+)-T-cell populations. Infect Immun. 2002;70:3493\u20139.","journal-title":"Infect Immun"},{"key":"1911_CR49","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.70.9.6497-6501.1996","volume":"70","author":"DE Brough","year":"1996","unstructured":"Brough DE, Lizonova A, Hsu C, Kulesa VA, Kovesdi I. A gene transfer vector\u2013cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol. 1996;70:6497\u2013501.","journal-title":"J Virol"},{"key":"1911_CR50","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.molimm.2006.11.003","volume":"44","author":"C Dobano","year":"2007","unstructured":"Dobano C, McTague A, Sette A, Hoffman SL, Rogers WO, Doolan DL. Mutating the anchor residues associated with MHC binding inhibits and deviates CD8+\u00a0T cell mediated protective immunity against malaria. Mol Immunol. 2007;44:2235\u201348.","journal-title":"Mol Immunol"},{"key":"1911_CR51","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1128\/IAI.55.3.604-608.1987","volume":"55","author":"Y Charoenvit","year":"1987","unstructured":"Charoenvit Y, Leef MF, Yuan LF, Sedegah M, Beaudoin RL. Characterization of Plasmodium yoelii monoclonal antibodies directed against stage-specific sporozoite antigens. Infect Immun. 1987;55:604\u20138.","journal-title":"Infect Immun."},{"key":"1911_CR52","unstructured":"WHO. World Malaria Report Geneva: World Health Organization. 2016; http:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2016\/report\/en\/."},{"key":"1911_CR53","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","volume":"365","author":"ST Agnandji","year":"2011","unstructured":"Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, et al. First results of phase 3 trial of RTS, S\/AS01 malaria vaccine in African children. N Engl J Med. 2011;365:1863\u201375.","journal-title":"N Engl J Med."},{"key":"1911_CR54","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","volume":"367","author":"ST Agnandji","year":"2012","unstructured":"RTS,S Clinical Trials Partnership, Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BG, et al. A phase 3 trial of RTS, S\/AS01 malaria vaccine in African infants. N Engl J Med. 2012;367:2284\u201395.","journal-title":"N Engl J Med."},{"key":"1911_CR55","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMoa1207564","volume":"368","author":"A Olotu","year":"2013","unstructured":"Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, et al. Four-year efficacy of RTS, S\/AS01E and its interaction with malaria exposure. N Engl J Med. 2013;368:1111\u201320.","journal-title":"N Engl J Med."},{"key":"1911_CR56","unstructured":"WHO. Malaria vaccine: WHO position paper. 2016. http:\/\/www.who.int\/wer\/2016\/wer9104\/en\/ ."},{"key":"1911_CR57","first-page":"1076","volume":"7","author":"SH Hodgson","year":"2014","unstructured":"Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA, et al. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis. 2014;7:1076\u201386.","journal-title":"J Infect Dis."},{"key":"1911_CR58","doi-asserted-by":"crossref","first-page":"286re5","DOI":"10.1126\/scitranslmed.aaa2373","volume":"7","author":"C Ogwang","year":"2015","unstructured":"Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med. 2015;7:286re5.","journal-title":"Sci Transl Med."},{"key":"1911_CR59","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","volume":"17","author":"NJ Sullivan","year":"2011","unstructured":"Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med. 2011;17:1128\u201331.","journal-title":"Nat Med."},{"key":"1911_CR60","doi-asserted-by":"crossref","first-page":"115ra1","DOI":"10.1126\/scitranslmed.3003155","volume":"4","author":"E Barnes","year":"2012","unstructured":"Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4:115ra1.","journal-title":"Sci Transl Med."},{"key":"1911_CR61","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","volume":"6","author":"L Swadling","year":"2014","unstructured":"Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med. 2014;6:261ra153.","journal-title":"Sci Transl Med"},{"key":"1911_CR62","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","volume":"376","author":"JE Ledgerwood","year":"2017","unstructured":"Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, et al. Chimpanzee adenovirus vector ebola vaccine. N Engl J Med. 2017;376:928\u201338.","journal-title":"N Engl J Med."},{"key":"1911_CR63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411627","author":"T Rampling","year":"2015","unstructured":"Rampling T, Ewer K, Bowyer G, Wright D, Imoukhuede EB, Payne R, et al. A monovalent chimpanzee adenovirus ebola vaccine\u2014preliminary report. N Engl J Med. 2015. doi: 10.1056\/NEJMoa1411627 .","journal-title":"N Engl J Med."},{"key":"1911_CR64","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1475-2875-10-65","volume":"10","author":"K Limbach","year":"2011","unstructured":"Limbach K, Aguiar J, Gowda K, Patterson N, Abot E, Sedegah M, et al. Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates. Malar J. 2011;10:65.","journal-title":"Malar J."},{"key":"1911_CR65","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3389\/fimmu.2013.00354","volume":"4","author":"S Flingai","year":"2013","unstructured":"Flingai S, Czerwonko M, Goodman J, Kudchodkar SB, Muthumani K, Weiner DB. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol. 2013;4:354.","journal-title":"Front Immunol."},{"key":"1911_CR66","doi-asserted-by":"crossref","first-page":"e78407","DOI":"10.1371\/journal.pone.0078407","volume":"8","author":"NN Padte","year":"2013","unstructured":"Padte NN, Boente-Carrera M, Andrews CD, McManus J, Grasperge BF, Gettie A, et al. A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates. PLoS ONE. 2013;8:e78407.","journal-title":"PLoS ONE."}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-017-1911-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T08:13:06Z","timestamp":1692864786000},"score":1,"resource":{"primary":{"URL":"http:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-017-1911-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,3]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1911"],"URL":"https:\/\/doi.org\/10.1186\/s12936-017-1911-z","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,3]]},"article-number":"263"}}